Literature DB >> 29026847

Intralesional Bevacizumab (Avastin®) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis.

Mohsen Pourazizi1,2, Sattar Kabiri3, Bahareh Abtahi-Naeini4.   

Abstract

Entities:  

Year:  2017        PMID： 29026847      PMCID： PMC5632942          DOI： 10.4103/jrpp.JRPP_17_38

Source DB:  PubMed          Journal:  J Res Pharm Pract        ISSN： 2279-042X


× No keyword cloud information.
  13 in total

1.  Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution.

Authors:  Suqin Guo; Nina Ni
Journal:  Arch Ophthalmol       Date:  2010-02

Review 2.  Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.

Authors:  Deborah K VanderVeen; Michele Melia; Michael B Yang; Amy K Hutchinson; Lorri B Wilson; Scott R Lambert
Journal:  Ophthalmology       Date:  2017-03-22       Impact factor: 12.079

Review 3.  Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Authors:  Ted Shih; Celeste Lindley
Journal:  Clin Ther       Date:  2006-11       Impact factor: 3.393

Review 4.  ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.

Authors:  Matthew P Simunovic; David A L Maberley
Journal:  Retina       Date:  2015-10       Impact factor: 4.256

5.  Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

Authors:  Angelo M Minnella; Cristina M Savastano; Lucia Ziccardi; Andrea Scupola; Benedetto Falsini; Emilio Balestrazzi
Journal:  Acta Ophthalmol       Date:  2008-09       Impact factor: 3.761

6.  Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Authors:  J Fernando Arevalo; Jans Fromow-Guerra; Juan G Sanchez; Mauricio Maia; Maria H Berrocal; Lihteh Wu; Mario J Saravia; Rogerio A Costa
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

7.  Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Authors:  Cornelia Halin; Hermann Fahrngruber; Josef G Meingassner; Guido Bold; Amanda Littlewood-Evans; Anton Stuetz; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 8.  A practical guide to treatment of infantile hemangiomas of the head and neck.

Authors:  Jia Wei Zheng; Ling Zhang; Qin Zhou; Hua Ming Mai; Yan An Wang; Xin Dong Fan; Zhong Ping Qin; Xv Kai Wang; Yi Fang Zhao
Journal:  Int J Clin Exp Med       Date:  2013-10-25

9.  Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis.

Authors:  J Chang; D Most; S Bresnick; B Mehrara; D S Steinbrech; J Reinisch; M T Longaker; A E Turk
Journal:  Plast Reconstr Surg       Date:  1999-01       Impact factor: 4.730

10.  Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial.

Authors:  Ali Asilian; Fatemeh Mokhtari; Atefeh Sadat Kamali; Bahareh Abtahi-Naeini; Mohammad Ali Nilforoushzadeh; Shayan Mostafaie
Journal:  Adv Biomed Res       Date:  2015-11-30
View more
  1 in total

1.  Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents.

Authors:  Bahareh Abtahi-Naeini; Ali Saffaei; Mahdi Hadian
Journal:  J Res Pharm Pract       Date:  2019-10-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.